Logo

Soligenix's RiVax Receives the US FDA's Fast Track Designation for the Prevention of Ricin Poisoning

Share this

Soligenix's RiVax Receives the US FDA's Fast Track Designation for the Prevention of Ricin Poisoning

Shots:

  • The US FDA has granted FT designation to RiVax (heat stable ricin toxin vaccine) to prevent ricin intoxication. Soligenix will submit BLA for the vaccine on a rolling basis- letting the FDA review sections of the BLA prior to receiving the complete submission
  • FDA’s FT designation is intended to facilitate the development and expedite the review of new drugs and biologics and is granted to the therapy
  • RiVax is Soligenix's heat-stable recombinant subunit vaccine- developed to prevent exposure to ricin toxin- comprising of the genetically altered version of a Ricin Toxin A (RTA) chain containing two mutations that inactivate the toxicity of the ricin molecule

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: American Pharmacy News


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions